These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 23160468)

  • 21. Sperm protein 17 (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk.
    Chiriva-Internati M; Wang Z; Xue Y; Bumm K; Hahn AB; Lim SH
    Eur J Immunol; 2001 Aug; 31(8):2277-83. PubMed ID: 11477539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients.
    Gao L; Xue SA; Hasserjian R; Cotter F; Kaeda J; Goldman JM; Dazzi F; Stauss HJ
    Transplantation; 2003 May; 75(9):1429-36. PubMed ID: 12792492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
    Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions.
    D'Sa S; Peggs K; Pizzey A; Verfuerth S; Thuraisundaram D; Watts M; White H; Hale G; Waldmann H; Goldstone A; Mackinnon S; Yong K
    Br J Haematol; 2003 Oct; 123(2):309-22. PubMed ID: 14531914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Wilms' tumor antigen 1-specific T lymphocyte generation soon after nonmyeloablative allergenic stem-cell transplantation in acute and chronic leukemia patients.
    Wei L; Zuo H; Sun X; Liu T; Guo M; Liu G; Sun Q; Qiao J; Wang D; Yu C; Hu K; Dong Z; Ai H
    Int J Hematol; 2010 May; 91(4):652-60. PubMed ID: 20376582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
    Davies JK; Hassan S; Sarker SJ; Besley C; Oakervee H; Smith M; Taussig D; Gribben JG; Cavenagh JD
    Br J Haematol; 2018 Feb; 180(3):346-355. PubMed ID: 29076145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.
    Smith E; Devlin SM; Kosuri S; Orlando E; Landau H; Lesokhin AM; Chung DJ; Hassoun H; Lendvai N; Landgren O; Giralt S; Chari A; Jagannath S; Koehne G
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):258-267. PubMed ID: 26325439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma.
    Orsini E; Alyea EP; Chillemi A; Schlossman R; McLaughlin S; Canning C; Soiffer RJ; Anderson KC; Ritz J
    Biol Blood Marrow Transplant; 2000; 6(4):375-86. PubMed ID: 10917573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Giralt S; Hester J; Huh Y; Hirsch-Ginsberg C; Rondón G; Seong D; Lee M; Gajewski J; Van Besien K; Khouri I; Mehra R; Przepiorka D; Körbling M; Talpaz M; Kantarjian H; Fischer H; Deisseroth A; Champlin R
    Blood; 1995 Dec; 86(11):4337-43. PubMed ID: 7492795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation.
    Weber G; Karbach J; Kuçi S; Kreyenberg H; Willasch A; Koscielniak E; Tonn T; Klingebiel T; Wels WS; Jäger E; Bader P
    Leukemia; 2009 Sep; 23(9):1634-42. PubMed ID: 19357702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treg-protected donor lymphocyte infusions: a new tool to address the graft-versus-leukemia effect in the absence of graft-versus-host disease in patients relapsed after HSCT.
    Di Ianni M; Olioso P; Giancola R; Santarone S; Natale A; Papalinetti G; Villanova I; Baldoni S; Di Tommaso A; Bonfini T; Accorsi P; Di Bartolomeo P
    Int J Hematol; 2017 Dec; 106(6):860-864. PubMed ID: 28721499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wilms' tumor 1-specific cytotoxic T lymphocytes can be expanded from adult donors and cord blood.
    Krishnadas DK; Stamer MM; Dunham K; Bao L; Lucas KG
    Leuk Res; 2011 Nov; 35(11):1520-6. PubMed ID: 21774984
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia.
    Bornhäuser M; Thiede C; Platzbecker U; Kiani A; Oelschlaegel U; Babatz J; Lehmann D; Hölig K; Radke J; Tuve S; Wermke M; Wehner R; Jähnisch H; Bachmann MP; Rieber EP; Schetelig J; Ehninger G; Schmitz M
    Blood; 2011 Jun; 117(26):7174-84. PubMed ID: 21540460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.
    Warren EH; Fujii N; Akatsuka Y; Chaney CN; Mito JK; Loeb KR; Gooley TA; Brown ML; Koo KK; Rosinski KV; Ogawa S; Matsubara A; Appelbaum FR; Riddell SR
    Blood; 2010 May; 115(19):3869-78. PubMed ID: 20071660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
    Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation.
    Schetelig J; Kiani A; Schmitz M; Ehninger G; Bornhäuser M
    Cancer Immunol Immunother; 2005 Nov; 54(11):1043-58. PubMed ID: 15887014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Results of Prophylactic Donor Lymphocyte Infusions for Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation.
    Gröger M; Gagelmann N; Wolschke C; von Pein UM; Klyuchnikov E; Christopeit M; Zander A; Ayuk F; Kröger N
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1399-1405. PubMed ID: 29684563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy.
    Rezvani K; Yong AS; Mielke S; Savani BN; Jafarpour B; Eniafe R; Le RQ; Musse L; Boss C; Childs R; John Barrett A
    Cancer Immunol Immunother; 2012 Jul; 61(7):1125-36. PubMed ID: 22198310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. WT1-targeted immunotherapy of leukaemia.
    Xue S; Gao L; Gillmore R; Bendle G; Holler A; Downs AM; Tsallios A; Ramirez F; Ghani Y; Hart D; Alcock S; Tranter A; Stauss HJ; Morris E
    Blood Cells Mol Dis; 2004; 33(3):288-90. PubMed ID: 15528146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.
    Waller EK; Boyer M
    Bone Marrow Transplant; 2000 May; 25 Suppl 2():S20-4. PubMed ID: 10933181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.